ANNUAL REPORT DIVISION OF SURGICAL ONCOLOGY FOR …



ACADEMIC ANNUAL REPORT DIVISION OF SURGICAL ONCOLOGY - 2003

Submitted by: Walley J Temple, MD FRCSC FACS

Professor & Chief of Division

The Division of Surgical Oncology, Department of Oncology, University of Calgary, Foothills Medical Centre/Tom Baker Cancer Centre continues development in its academic, service, and research components.

Service: We look forward to the addition of Neurosurgical Oncology.

The Hepatobilary Clinic is now established with a full hepatobiliary group within the Cancer Centre. This has resulted in all significant hepatobiliary surgery for cancer in southern Alberta being located within the purview of the Cancer Centre and the University of Calgary. This group has been very active in developing a synoptic surgical record and follow-up template. They continue to accrue patients in a prospective trial on the management of liver metastases using a preoperative or neoadjuvant chemotherapy.

A number of new procedures continue to be introduced into the armamentarium of surgery which are either only found in Calgary or in only a few centres throughout Canada. This includes intraperitoneal chemotherapy for advanced colorectal disease into the peritoneum, pseudomyxoma peritonei, appendix cancer, and other primary peritoneal tumors. It also includes the selective management of advanced hepatic tumors utilizing radiofrequency ablation, selective hepatic portal vein ligation, and preoperative chemotherapy. A new technique for limb perfusion has been introduced for metastatic melanoma and other cutaneous tumors. The Endocrine Surgery Group has developed a unique team where cooperation between Edmonton and Calgary is frequent with surgery, nuclear medicine, chemotherapy, and molecular targets. The Endocrine Tumor Clinic is one of the few such clinics in the world and continues to make progress on a number of rare tumors including carcinoid tumors and thyroid tumors.

Research: The efforts of the Cancer Surgery Working Group have resulted in a submission to the provincial government for funding for the entire province to introduce synoptic reporting for colon cancer, breast cancer, hepatobiliary cancer, and sarcoma. The first synoptic approach will be introduced for hepatobiliary tumors.

The quality of life study for 150 breast cancer patients, followed now for 6 years, is starting to analyze the results. The study is almost completed.

Funding continues in many areas of research, including breast cancer, hepatobiliary, immunology, and melanoma. We remain involved in international trials in melanoma and breast cancer. We are looking at the electro-characteristics of breast cancer and work to date has generated a paper on the use of this potential new diagnostic modality. Overall grant funding for our members is approximately $1.9 million.

The publications number 32 for the group for the past year with provincial, national, and international presentations numbering 80.

Administration: Members of the group continue to be active as President of the Canadian Society of Surgical Oncology, as Editors of the Journal of Surgical Oncology and Seminars in Surgical Oncology, in the Royal College Surgical Oncology Training Program Group, as Co-founder and 1st President of the Canadian Hepato-Pancreato-Biliary Society, as Vice-Chair of the American College of Surgeons, and as leader in the development of the Calgary Breast Program, to name some of the highlights.

Education: Significant awards and successes have accrued in the educational area. The Surgical Oncology Training Program is now approved by the prestigious American Society of Surgical Oncology. We continue to train 2 residents – 1 in endocrine surgical oncology and 1 in general surgical oncology. We continue to have General Surgery Residents rotate through our program spending increasing time in surgical oncology to keep up with the current advances. Our members include the Chair of the University of Calgary Surgical Oncology Training Program which is Royal College approved and Chair of the General Surgery Training Program, also Royal College approved. We continue to have our Surgical Oncology Day and were fortunate in 2003 to have as our guest Dr Charles Balch, Executive Vice President and CEO of ASCO. This year we look forward to having a leader in hepatobiliary surgery from Toronto, Dr Steve Gallinger. There have been some awards to members in our division including the Royal College of Physicians and Surgeons Mentor of the Year Award.

Overall our division has continued development in all areas and we are extremely grateful for the support of the Alberta Cancer Board and the University of Calgary which have made this all possible.

Annual reports surg oncol tbcc 2003 academic report feb 04.doc/ldh

MEMBERS - Division of Surgical Oncology

John P Arlette 403 216 4685 Fax 403 216 4689 E mail arlette@

Publications

Bienert T, Trotter M, Arlette J. Malignant melanoma of the face treated with Mohs micrographic surgery. J Cutan Med Surg 2003 Jan-Feb; 7(1):25-20.

Oliver F Bathe 403 670 2098 Fax 403 283 1651 E mail bathe@ucalgary.ca

Publications

Bathe OF, Mies C, Casillas J, Franceschi D, Liningstone AS. Massive hemorrhage and infarction complicating focal nodular hyperplasia: Case report and literature review. HPB Surgery 2003; 5:123-126.

Bathe OF, Dalyot-Herman N, Malek RE. Therapeutic limitations in tumor-specific CD8+ Memory T cell engraftment. BMC Cancer 2003; 3:21.

Grants

Tumor immunity vs autoimmunity following cellular immunotherapy

Source: American College of Surgeons (Faculty Research Award)

Awarded: $US 40,000/year

Dates of Approved Project: July 2003 – July 2004

Name of PI: Oliver F. Bathe

Tumor immunity as a function of autoimmunity

Source: Cancer Research Society

Awarded: $60,000/year

Dates of Approved Project: September 2003 – September 2005

Name of PI: Oliver F. Bathe

Refining the ‘danger’ hypothesis in the context of the immune response against tumor

Source: University of Calgary Department of Surgery Young Faculty Research Award

Awarded: $75,000

Dates of Approved Project: September 2003 – September 2004

Name of PI: Oliver F. Bathe

Neoadjuvant 5-FU + leucovorin + CPT-11 for liver metastases from colorectal adenocarcinoma

Source: Pfizer Canada Inc

Awarded: $308,000

Dates of Approved Project: 2003 – 2006

PI: Oliver F. Bathe

A Phase III double-blind multi-centre randomized study in chemo-naïve patients with locally advanced or metastatic pancreatic cancer to compare a combination therapy of virulizin + gemcitabine + placebo vs placebo + gemcitabine

Source: Lorus Therapeutics Inc

Awarded: $9,743.50/patient

Dates of Approved Project: ongoing

Name of PI: Oliver F. Bathe

W Donald Buie 403 670 2020 Fax 403 8004 E mail wdbuie@ucalgary.ca

Publications

Topstad DR, Panaccione R, Johnson JA, MacLean AR, Buie WD. Combined seton placement, infliximab infusion and maintenance. Dis Colon & Rectum 2003 May; 46(5):577-83.

Grants

Opioid-induced postoperative ileus

Adalor Corporation

$3,800/patient

Anastomosis trail for Crohn’s disease

Crohn’s & Colitis Foundation

$1,000/patient

Perioperative stress dose steroids

CHR/Department of Surgery

$7,460

Pathology-guided treatment in rectal cancer

National Cancer Institute of Canada

$1,700/patient

Remicade for perianal Crohn’s

CHR/Department of Surgery/Foothills Medical Centre

PI

Outbreak of clostridium difficile colitis caused by clindamycin-resistant strain associated with increased rate of surgical intervention

CHR/Department of Surgery/Foothills Medical Centre

PI

Hypoxia and anastomotic leaking

CHR/Department of Surgery/Foothills Medical Centre

Co-Investigator

Timing of rectal cancer – Response to chemoradiation

NIH

$200,000/$30,000

PI

5-year Provincial outcomes following resection for rectal cancer

Cancer Surgery Working Group, Alberta Cancer Board

PI

$12,000

Scoring system for anastomotic leak

CHR/Department of Surgery/Foothills Medical Centre

Co-investigator

Incontinence following chemoradiation for rectal cancer

CHR/Department of Surgery/Foothills Medical Centre

Co-investigator

Portal venous thrombosis following ileopouch procedure

CHR/Department of Surgery/Foothills Medical Centre

Co-investigator

Colonoscopy surveillance following resection for colorectal cancer

CHR/Department of Surgery/Foothills Medical Centre

Co-investigator

Late recurrence following curative resection

CHR/Department of Surgery/Foothills Medical Centre

PI

William G de Haas 403 571 3150 Fax 403 571 3133

Elijah Dixon 403 944 8323 Fax 403 283 1651 E mail elijah.dixon@calgaryhealthregion.ca

Publications

Dixon E, Vollmer Jr CM, Greig PD, Gallinger S. HPB Clinics around the world- The University of Toronto HPB program at the Toronto General Hospital. HPB 2003; 5(1):39-42.

Vollmer CM, Dixon E, Sahajpal A, Cattral MS, Grant DR, Taylor BR, Gallinger S, Greig PD. Abstract – Extended hepatic resections-increased risk with biliary resection and reconstruction. J Gastrointest Surg 2003 Feb; 7(2)L282-283.

Vollmer CM, Dixon E, Guindi M, Grant DR, Cattral MS, Gallinger S, Greig PD. Abstract – Ablation of hepatocellular carcinoma (HCC) prior to transplantation-pathologic analysis of the explant. J Gastrointest Surg 2003 Feb; 7(2):266.

Sutherland F, Dixon E, Bathe O, Anderson M. Abstract – Anatomic studies of the hepatocaval ligament. J Gastrointest Surg 2003 Feb; 7(2).280.

Dixon E, Sutherland FR, Vollmer Jr CM, Greig PD. Bile duct injury following laparoscopic cholecystectomy: Resection of the entire extrahepatic/pancreatic tree. J American College of Surgeons 2003 Nov; 197(5):862-863.

Grants

The effect that the presence of liver transplantation programs and comprehensive cancer centers have on patient outcome following liver resection in the United States.

Centre for the Advancement of Health, Calgary

$7,500.00

Joseph C Dort 403 220 4307 Fax 403 220 3145 E mail jdort@ucalgary.ca

Publications

Sywak M, Pasieka JL, McFadden S, Gelfand G, Terrell J, Dort J.Functional results and quality of life fter tracheal resection for locally invasive thyroid cancer. Am J Surg 2003; 185:462-4767.

Lobay K, Dort J. Varaztad Kazanjian: Life and time. Proceedings of the History of Medicine Days Journal. 2003; 135-140.

Grants

Alberta Health & Wellness Health Innovation Fund

Operating Grant

2003

Universal Newborn Hearing Screening Program in Alberta

Principal Investigator

Awarded $143,000

Private donation - $25,000

Private donation - $200,000

Gary A J Gelfand 403 944 4268 Fax 403 270 8431 E mail gelfand@ucalgary.ca

Publications

Sywak M, Pasieka JL, McFadden S, Gelfand G, Terrell J, Dort J.Functional results and quality of life fter tracheal resection for locally invasive thyroid cancer. Am J Surg 2003; 185:462-4767.

Rene Lafreniere 403 944 1697 Fax 403 270 8409 E mail rlafreni@

Publications

Lafrenière R. Ethical issues in surgical treatment and research. Curr Probl Surg 2003 Jul; 40(7):353-448.

Grants

Alberta Cancer Board RIP Grant

Institute for Health Economics

Anonymous Donor

Total for reporting year - $342,360

Robert L Lindsay 403 571 3155 Fax 403 3138

Enzio Magi 403 571 3130 Fax 403 571 3133

Sean McFadden 403 944 4268 Fax 403 270 8431

E mail sean.mcfadden@calgaryhealthregion.ca

Publications

Sywak M, Pasieka J, McFadden S, Gelfand G, Terrell, Dort J. Functional results and quality of life following tracheal resection for locally invasive thyroid cancer. Am J Surg 2003; 185:462-467.

Kneafsey P, Duggan M, McFadden S. Fine needle aspiration cytology of pulmonary, well-differentiated fetal adenocarcinoma prepared by the ThinPrep® method. Cytopathology 2003; 14:87-90.

Grants

NCIC-BR 19 – A Phase III prospective randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor antagonist, ZD 1839 (IRESSA) in completely resected primary Stage IB, II, IIIA non-small cell lung cancer.

Local principal investigator

J Gregory McKinnon 403 944 2844 Fax 403 283 1651 E mail mckinnon@ucalgary.ca

Publications

Li LL, Scolyer RA, Ka VSK, McKinnon JG, Shaw HM, McCarthy SW, Thompson JF. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: A clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am J Surg Path. 2003; 27(9):1197-1202.

McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: Long-term survival data from the New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cance. 2003 Sep 15; 98(6):1223-31.

Thompson SK, McKinnon JG, Ghali WA. Perioperative stroke occurring in patients who undergo neck dissection for head and neck cancer: Unanswered questions. Can J Surg 2003; 46(5):332-334.

Daphne JY Mew MD 403 220 2859 Fax 403 283 4841 E mail dmew@ucalgary.ca

Grants

Preoperative PET Imaging in Breast Cancer Patients: Correlation with Histologic Findings of Sentinel Node Biopsies and Axillary Dissection (Drs. D. Severin, D. Mew)

Alberta Cancer Board

$100,926.60

Ongoing

Co-investigator.

Micrometastasis in Bone Marrow of Patients Undergoing Primary Surgery for Newly-Diagnosed Breast Cancer (Drs S. Gluck, A. Magliocco and D. Mew)

$99,412

Ongoing

Co-investigator.

Janice L Pasieka MD 403 944 2491 Fax 403 283 4130

E mail janice.pasieka@calgaryhealthregion.ca

Publications

Sywak M, Romano C, Raber E, Pasieka JL. Septic thrombophlebitis of the inferior mesenteric vein from sigmoid diverticulitis. J Am College of Surgeons 2003; 196(2):326-327.

Pasieka JL. Anaplastic thyroid cancer. Current Opinion in Oncology. 2003; 15(1):78-83.

Pasieka JL. Surgical approach to secondary hyperparathyroidism. Problems in General Surgery. 2003; 20(3):61-67.

Sywak M, Pasieka JL, McFadden S, Gelfand G, Terrell J, Dort J.Functional results and quality of life fter tracheal resection for locally invasive thyroid cancer. Am J Surg 2003; 185:462-4767.

Pasieka JL. Asymptomatic primary hyperthyroidism: Standards and guidelines for diagnosis and management in Canada. Endocrine Practice 2003; 9(5):400-405.

Norman S Schachar MD 403 220 2880 Fax 403 270 3927 E mail nsschach@ucalgary.ca

Grants

Osteochondral Transplantation for Repair of Joint Surface Injury

Canadian Institute of Health Research

Awarded: $359, 806

Dates of approved project: 2002 – 2006

Principal investigator

Francis R Sutherland 403 944 8323 Fax 403 283 1651

E mail francis.sutherland@calgaryhealthregion.ca

Publications

Ashton J, Sutherland F, Nixon J, Nayak V. A case of solid pseudopapillary tumor of the pancreas: Preoperative cyst fluid analysis and treatment by enucleation. Hepatogastroenterology 2003; 50:2239-2241.

Sutherland F, Cunningham J, Pontikes L, Parsons L, Klassen J. Elevated serum interleukin 6 levels in patients with acute intestinal ischemia. Hepatogastroenterology 2003; 50:419-421.

Qin H, Goldstein L, Iwanicki S, Mackay E, Sutherland F. Hyperlipemic pancreatitis and pseudocyst formation in late pregnancy. Hepatogastroenterology 2003; 50:870-872.

Cooke M, Dunham M, Sutherland F. Soft tissue images: Proximal gastrointestinal stromal tumor. Can J Surg 2003; 46:121-122.

McCullough L, Sutherland F, Preshaw R. Gallstone pancreatitis: Does discharge and readmission affect outcome. HPB2003; 5:96-99.

Medlicott S. Beaudry P, Morris G, Hollaar G, Sutherland F. Intestinal thromboangitis obliterans in a woman: A case report and discussion of chronic ischemic changes. Can J Gastroenterol 2003; 17:559-561.

Dixon E, Sutherland FR, Vollmer Jr CM, Greig PD. Bile duct injury following laparoscopic cholecystectomy: Resection of the entire extrahepatic/pancreatic tree. J American College of Surgeons 2003 Nov; 197(5):862-863.

Walley J Temple MD 403 944 1914 Fax 403 283 1651

E mail walleyte@cancerboard.ab.ca

Publications

Sampath S, Temple CL, Temple WJ. Precision handling of the sentinel node. J Surg Oncol 2003; 84(3):176-7.

Temple WJ. Editorial – Global issues in surgical oncology. J Surg Oncol 2003. 83:61.

Grants

Multicenter Selective Lymphadenectomy Trial (MSLT).

John Wayne Cancer Centre/ NIH –

$US 21,000 + 1,450/patient accrued

Ongoing

Co-investigator

Phase III randomized double-blind pivotal trial of immunotherapy with BCG plus a polyvalent melanoms vaccine, CancerVaxSYMBOL 227\f”Symbol”\s 10 versus BCG plus a placebo as a post-surgical treatment for Stage III and Stage IV melanoma.

Cancer Vax Vaccine Corp/National Institute of Health

$US 6,000/Stage III patient, $2,305/Stage IV patient accrued

Ongoing

Co-investigator

Alberta Cancer Foundation. Visiting scholar grant. Support to bring international speaker as guest to annual Surgical Oncology Symposium - $3,000

Johnson & Johnson. Educational grant. Support for annual Surgical Oncology Symposium - $500

Novartis Pharma Canada Inc. Educational grant. Support for annual Surgical Oncology Symposium - $500

Partners in Health/ATCO Surgical Oncology Fund. Research operating continuation grant to support breast cancer study - $27,220.

Schering Canada. Educational grant. Support for annual Surgical Oncology Symposium - $3500

Private donation from family to Richardson Surgical Oncology Fund. Research Grant. $5,000

Private donations from cancer patients/families for cancer research support - $1,000

Private donation from ATCO Group to surgical oncology through Alberta Cancer Foundation - $25,000

Annual reports surg oncol tbcc 003 academic report feb 04.doc/ldh

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download